Arrevus, Inc.

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  AbbVie's president tacks on COO duties after Rick Gonzalez teases succession plan AbbVie We here at Chutes & Ladders incorporated have been reading a great book lately; it's called "Tea Leaves." It has very little substance and virtually no plot line, but it's incredibly entertaining. Oh and would you look at that, AbbVie has a new chief operating officer months after Rick Gonzalez teased a potential succession plan. The company has added the responsibilities to the plate of president and finance czar Robert Michael. Much ado about nothing? Perhaps!  All jokes aside, the company has said nothing to the effect of Michael being the next in line for the chief executive job whenever Gonzalez decides to hang it up. It was only two months ago that the longtime CEO even mentioned the prospect of departing, though he said he's had "many, many" discussions with the board about it. Using his LinkedIn profile as a guide, Michael has worked his entire career—more than 30 years—at either Abbott or AbbVie. In 2018, he was promoted from VP and corporate comptroller to chief financial officer and last year was named president.  The company had little to add about his appointment in a Securities and Exchange Commission disclosure beyond saying that he'd be continuing to oversee the company's "global commercial and financial operations." Oh, but that's not all.  "He will also be responsible for operations, human resources, business development and corporate strategy," the disclosure reads. Disclosure Emergent CEO Robert Kramer retires a 2nd time after tumultuous few years Emergent  If at first you don’t like retirement, come back and work through a 1-in-100-year global emergency and retire shortly after that. We’re pretty sure that’s the saying, but don’t quote us. Such was the last 12 years of Robert Kramer’s second stint at Emergent BioSolutions. He retired in 2010 only to be enticed back to the role a year later, becoming CEO in 2018. His second go-around leading the CDMO was pretty par for the course until the COVID pandemic spurred a wicked pendulum swing. As one of the major producers of COVID vaccines for companies, Emergent’s share price almost tripled.  But manufacturing missteps and ruined batches sent the company into a tailspin, namely 15 million doses of J&J vaccine that had to be thrown out after an ingredient mix-up. To make matters worse, Kramer was under federal investigation after selling $10 million in stock before the company disclose the manufacturing screw-up.  The incident puts a stain on Kramer’s tenure that was largely defined by corralling lucrative government contracts for pandemic preparedness. Over the years, Emergent has been tasked with producing medicines to defend against anthrax, smallpox and Ebola. Fierce Pharma Deborah Dunsire retires from Lundbeck after record quarter Lundbeck  Ending on a high note is always easier said than done, as leaders regardless of industry often feel like there’s more to accomplish when the wind is in their sails. But Deborah Dunsire knows better, for now. Lundbeck’s CEO of nearly five years is retiring after the company scored record-high revenue last quarter, with 19% growth compared to the first three months of 2022.  The company has been bolstered by antipsychotic med Rexulti, approved to treat schizophrenia and as an add-on therapy to treat major depressive disorder. The med also recently nabbed FDA approval to treat agitation in patients with Alzheimer’s disease. Replacing Dunshire is Charl van Zyl, head of neurology solutions at UCB. He joined the Belgian pharmaceutical company in 2017 as head of corporate operations before moving to the neurology business. Fierce Pharma > ICER founder Steve Pearson is handing over the president reins to COO Sarah Emond after 17 years at the helm. Emond has been in that role since she joined the organization as the third employee in 2009. Fierce Pharma > Immunome and Morphimmune are coming together as one through a reverse merger, putting Clay Siegall, Ph.D.—who left his role as CEO of Seagen last year after being arrested for domestic abuse—in the chief executive chair. Fierce Biotech   > Appia Bio has added two industry vets to its team: Sylvaine Cases, Ph.D., as chief business officer and Alex Babayan, Ph.D., as vice president and head of regulatory affairs. Cases joins the CAR-NKT biotech with a leadership track record at LynxBio, Johnson & Johnson and Sanofi, while Babayan has more than a decade of global regulatory affairs experience in cancer cell therapy, including at Gilead’s Kite. Release > Sasha Damouni Ellis has left Marinus Pharmaceuticals to become Vir Biotechnology’s EVP and chief corporate affairs officer, starting July 10. Ellis was previously Marinus’ SVP of corporate affairs and investor relations and also served as Bayer’s U.S. director of external communications and media relations. Release > Blueprint Medicines co-founder Alexis Borisy lost a majority vote for his directorship at the company during its annual meeting June 21. However, Borisy hangs on to the position because he still got reelected by a plurality standard. Fierce Pharma > ABVC BioPharma has tapped Uttam Yashwant Patil, Ph.D., to lead as CEO. Patil was previously chief operating officer and chief scientific officer of BioKey, a GMP-certified facility owned by ABVC. Release > Despite the controversy surrounding a relationship with departing director Alex Denner, Susan Langer has secured enough investor support to join Biogen’s board. Fierce Pharma > InflaRx has tapped Camilla Chong, M.D., to serve as chief medical officer. Chong joins from Kyowa Kirin, where she was VP and global medical affairs therapy area head for immunology, and has also worked at Pfizer, GSK and Teva Pharmaceuticals. Release > Eiger BioPharmaceuticals' interim CEO David Apelian has been promoted to the permanent role after taking the reins in December. His first order of business is tightening the company’s fiscal belt, including laying off 25% of staff. Fierce Biotech > London-based biotech Duke Street Bio is welcoming Jeff Thompson, Ph.D., on as head of clinical operations. Thompson most recently served as a senior director of clinical programs for AstraZeneca UK. Release > Nymox Pharmaceutical has fired both Chief Financial Officer Christopher Riley and Chief Operating Officer Randall Lanham. The Canada-based company has launched a search for a new CFO. Release > Rivus Pharmaceuticals has tapped its executive chair Jayson Dallas, M.D., as CEO, taking the reins from Allen Cunningham, who will transition to chief operating officer. Dallas previously served as CEO of Aimmune Therapeutics and has held leadership roles at Ultragenyx Pharmaceutical, Genentech and Roche. Release > Alloy Therapeutics is bringing on Michael Schmidt, Ph.D., as chief scientific officer, while promoting Martin Leach, Ph.D., from his role as SVP of global informatics to chief operating officer. New CSO Schmidt most recently served as CSO at Ankyra Therapeutics. Release > Clinical-stage biotech Evommune has selected J. Mark Jackson, M.D., to serve as VP of clinical development. Jackson has previously worked as an adviser to multiple companies including Abbvie, Amgen, Bristol Myers Squibb, J&J’s Janssen, Eli Lilly, Novartis and Pfizer. Release > Lumos Pharma’s chief medical officer David Karpf, M.D., is departing. While the company searches for a new CMO, Lumos’ SVP of global clinical development and medical affairs Pisit “Duke” Pitukcheewanont, M.D., will oversee clinical activities. Release > Rallybio’s president, chief operating officer and co-founder Stephen Uden, M.D., is becoming the company’s CEO starting Aug. 1. He’ll succeed Martin Mackay, Ph.D., chairman of the board and co-founder, who will take on the role of executive chair. Release > Aquestive Therapeutics has appointed Carl Kraus, M.D., as chief medical officer. Kraus joins from Aceragen and previously founded and served as the CEO of Arrevus until its sale to Aceragen in 2021. Release

Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024. For Idera, the merger is something of a lifeline after its top drug candidate flopped last year. On the other side, Aceragen is now a publicly traded company less than two years after launching. The all-stock deal will leave the merged companies with $26 million on hand. Executives said this is enough cash to fund operations through August 2023. That’s when key data readouts from clinical trials are expected. Idera shareholders will end up with 33% of the combined company, which will continue to trade publicly under Idera’s stock symbol IDRA. But it’s Aceragen’s pipeline that will become the focus of the new company, and Aceragen’s executives will fill most of the new company’s top posts. Idera reported a second-quarter loss of $5.3 million compared with a $7.6 million loss over the same period last year. The merger comes after the March 2021 failure of Idera’s pivotal Phase III trial of tilsotolimod, a synthetic Toll-like receptor 9 agonist, as a treatment for melanoma. The molecule was Idera’s star product. Its failure prompted the Philadelphia-area company to look for 'strategic alternatives',” said Idera CEO Vincent Milano during a conference call Wednesday. Aceragen’s lead drug candidates are ACG-701 for cystic fibrosis and melioidosis patients. ACG-701 is the company’s take on sodium fusidate, a 50-year-old antibiotic. Aceragen’s formulation of sodium fusidate is meant to treat acute pulmonary exacerbations, a life-threatening infection, in cystic fibrosis patients. The FDA granted Orphan, Fast Track and Qualified Infectious Disease Product status to ACG-701 for this indication. Phase II clinical trial enrollment is expected to start by the end of the year. Aceragen also received a $51 million grant from the U.S. Defense Threat Reduction Agency to develop sodium fusidate as a potential medical countermeasure to melioidosis, a bacterial infection commonly known as Whitmore’s disease. ACG-701 is undergoing Phase II clinical trial testing. The company is targeting the U.S. government for a contract to add to the national stockpile if approved. “We believe the commercial potential of both these programs is strong,” said Aceragen CEO John Taylor during the call. Taylor was also appointed CEO of the new company. Aceragen Chief Medical Officer Carl Kraus will serve the same role at the merged company, as will Chief Operating Officer Daniel Salain. Idera’s CEO Vincent Milano will become chair of the board. Idera’s General Counsel Bryant Lim and Chief Financial Officer John Kirby will remain in their roles at the new company. Aceragen launched in May 2021 with a $35 million investment from Raleigh, N.C.-based NovaQuest.The Durham, N.C.-based Aceragen last year acquired Arrevus, which was also developing treatments for rare diseases.

SEATTLE, June 22, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 10,263.5 million in 2022 and is expected to exhibit a CAGR of 9.0% over the forecast period (2022-2030). Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Key trends in market include widespread presence of acute bacterial skin and skin structure infections (ABSSSI); increasing approval of novel drugs for acute bacterial skin and skin structure infections (ABSSSI), and increasing collaborations, acquisitions, and partnerships among key players. These key trends are expected to aid in growth of the global acute bacterial skin and skin structure infections (ABSSSI) market. According to an article published in the PLOS One journal, a peer-reviewed open access scientific journal in July 2020, the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was found to be 64% (abscess and/or cellulitis), on the basis of data collected between October 2017 and March 2019. Moreover, rapid research and development in the field of acute bacterial skin and skin structure infections (ABSSSI) for development of novel treatment for the same is expected to fuel market growth over the forecast period. For instance, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be administered as a single- or two-dose regimen for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Furthermore, key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market are focusing on adoption of inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their market presence in the global market. For instance, in May 2020, Advanz Pharma, a U.K.-based pharmaceutical company, announced that it had completed the acquisition of Correvio Pharma Corp., a Canada-based specialty pharmaceutical company whose product portfolio includes licensed medicines such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Request Sample Copy of this Report @ Key Market Takeaways: Global acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising focus of market players on regulatory approvals for novel acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in July 2021, AbbVie Inc. ., a U.S. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered as an intravenous (IV) infusion for the treatment of pediatric patients with ABSSSI caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. Among infection type, community acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to rising drug launches by market players for treatment of community acquired acute bacterial skin and skin structure infections (ABSSSI). For instance, in February 2021, Paratek Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it is expanding commercial launch of its tetracycline-class oral antibiotic Nuzyra (omadacycline) into the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI). Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd. Request for Customization @ Detailed Segmentation: Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type: Oral & Parenteral Antibiotics Vancomycin Linezolid Clindamycin Ceftaroline Daptomycin Dalbavancin Tedizolid Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others) Topical Antibiotics Hydrogen Peroxide Fusidic Acid Mupirocin Retapamulin Povidone-Iodine Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type: Hospital Acquired ABSSSI Community Acquired ABSSSI Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration: Oral Parenteral Topical Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region: North America By Country: U.S. Canada Europe By Country: U.K. Germany Italy France Spain Russia Rest of Europe Asia Pacific By Country: China India Japan ASEAN Australia South Korea Rest of Asia Pacific Latin America By Country: Brazil Mexico Argentina Rest of Latin America Middle East & Africa By Country: GCC Countries Israel South Africa Rest of Middle East & Africa Buy this Complete Report Now @ Find related trending report below: North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market , by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: Follow Us: LinkedIn | Twitter Logo: SOURCE Coherent Market Insights